Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: March 14, 2024 | Amneal Pharmaceuticals, Inc. | |
|---|---|---|
| By: | /s/ Anastasios Konidaris | |
| Anastasios Konidaris | ||
| Executive Vice President, Chief Financial Officer(Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Chirag Patel | President, Co-Chief Executive Officer and Director | March 14, 2024 |
| Chirag Patel | (Co-Principal Executive Officer) | |
| /s/ Chintu Patel | Co-Chief Executive Officer and Director | March 14, 2024 |
| Chintu Patel | (Co-Principal Executive Officer) | |
| /s/ Anastasios Konidaris | Executive Vice President, Chief Financial Officer | March 14, 2024 |
| Anastasios Konidaris | (Principal Financial and Accounting Officer) | |
| /s/ Paul M. Meister | March 14, 2024 | |
| Paul M. Meister | Chairman of the Board and Director | |
| /s/ Jeffrey P. George | March 14, 2024 | |
| Jeffrey P. George | Director | |
| /s/ Emily Peterson Alva | March 14, 2024 | |
| Emily Peterson Alva | Director | |
| /s/ J. Kevin Buchi | March 14, 2024 | |
| J. Kevin Buchi | Director | |
| /s/ John J. Kiely, Jr. | March 14, 2024 | |
| John J. Kiely, Jr. | Director | |
| /s/ Ted Nark | March 14, 2024 | |
| Ted Nark | Director | |
| /s/ Gautam Patel | March 14, 2024 | |
| Gautam Patel | Director | |
| /s/ Shlomo Yanai | March 14, 2024 | |
| Shlomo Yanai | Director | |
| /s/ Deb Autor | March 14, 2024 | |
| Deb Autor | Director |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.